WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011146382) IMPROVED IMMUNOTHERAPEUTIC DOSING REGIMENS AND COMBINATIONS THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/146382    International Application No.:    PCT/US2011/036626
Publication Date: 24.11.2011 International Filing Date: 16.05.2011
IPC:
A61P 35/00 (2006.01), A61K 31/00 (2006.01), A61K 31/337 (2006.01), A61K 31/4164 (2006.01), A61K 31/427 (2006.01), A61K 31/555 (2006.01), A61K 31/58 (2006.01), A61K 31/655 (2006.01), A61K 39/00 (2006.01), A61K 39/395 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road Princeton, New Jersey 08543-4000 (US) (For All Designated States Except US).
HUMPHREY, Rachel Wallach [US/US]; (US) (For US Only)
Inventors: HUMPHREY, Rachel Wallach; (US)
Agent: D'AMICO, Stephen C.; Bristol-Myers Squibb Company P.O. Box 4000 Princeton, New Jersey 08543-4000 (US)
Priority Data:
61/345,334 17.05.2010 US
61/452,841 15.03.2011 US
Title (EN) IMPROVED IMMUNOTHERAPEUTIC DOSING REGIMENS AND COMBINATIONS THEREOF
(FR) RÉGIMES POSOLOGIQUES IMMUNOTHÉRAPEUTIQUES AMÉLIORÉS ET COMBINAISONS DE CEUX-CI
Abstract: front page image
(EN)The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of immunotherapeutic agents e.g. CTLA-4 antagonists such as 3pilimumab or Tremelimumab in combination with one or more chemotherapeutic agents in cancer patients.
(FR)L'invention présentement décrite concerne des régimes posologiques thérapeutiques et des combinaisons de ceux-ci pour utilisation dans l'augmentation de l'efficacité thérapeutique d'agents immunothérapeutiques, par exemple, des antagonistes de CTLA-4 tels que l'ipilimumab ou le trémélimumab en combinaison avec un ou plusieurs agents chimiothérapeutiques chez des patients cancéreux.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)